Retagliptin

Chemical structure of Retagliptin

Retagliptin is an oral antidiabetic drug belonging to the class of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors). It is used in the management of type 2 diabetes mellitus to improve glycemic control in adults. Retagliptin works by inhibiting the enzyme DPP-4, which results in increased levels of incretin hormones, thereby enhancing the secretion of insulin and reducing the levels of glucagon in the bloodstream.

Mechanism of Action

Retagliptin functions by selectively inhibiting the DPP-4 enzyme. This enzyme is responsible for the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preventing the breakdown of these hormones, Retagliptin increases their concentration and prolongs their activity. This leads to increased insulin release from the pancreatic beta cells and decreased glucagon release from the alpha cells, resulting in improved blood glucose control.

Pharmacokinetics

Retagliptin is administered orally and is rapidly absorbed from the gastrointestinal tract. It has a bioavailability of approximately 85%. The drug is metabolized primarily in the liver and excreted through the kidneys. The half-life of Retagliptin is approximately 12 hours, allowing for once-daily dosing.

Clinical Use

Retagliptin is indicated for the treatment of type 2 diabetes mellitus in adults. It is often used in combination with other antidiabetic medications such as metformin, sulfonylureas, or thiazolidinediones when diet and exercise alone do not provide adequate glycemic control. Retagliptin is not indicated for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Side Effects

Common side effects of Retagliptin include nasopharyngitis, headache, and upper respiratory tract infection. Some patients may experience hypoglycemia, especially when used in combination with other antidiabetic agents. Rare but serious side effects include pancreatitis and hypersensitivity reactions.

Contraindications

Retagliptin is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Caution is advised in patients with severe renal impairment or end-stage renal disease.

Related pages

• Dipeptidyl peptidase-4 inhibitors
• Type 2 diabetes mellitus
• Insulin
• Glucagon